Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas

Genes Chromosomes and Cancer

Volumn 20, Issue 1, 1997, Pages 24-29

  Herfarth, Klaus K F ^a   Wick, Mark R ^a   Marshall, Helen N ^a   Gartner, Elaina ^a   Lum, Sharon ^a   Moley, Jeffrey F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 17P; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MUTATION RATE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

ADRENAL GLAND NEOPLASMS; CARCINOMA, MEDULLARY; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; DNA PRIMERS; DNA, NEOPLASM; GENES, P53; GENETIC MARKERS; GENOTYPE; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; PHEOCHROMOCYTOMA; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030963645     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199709)20:1<24::AID-GCC4>3.0.CO;2-B     Document Type: Article

References (42)

1. Ausubel SM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (1990) Current Protocols in Molecular Biology. New York: John Wiley & Sons.
2. Biegel JA, Burk CD, Barr FG, Emanuel BS (1992) Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 52:3391-3395.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124.
4. Carbone D, Chiba I, Mitsudomi T (1991) Polymorphism at codon 213 within the p53 gene. Oncogene 6:1691-1692.
5. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H (1994) Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583.
6. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784.
7. Choi SW, Hytiroglou P, Geller SA, Kim SM, Chung KW, Park DH, Theise ND, Thung SN (1993) The expression of p53 antigen in primary malignant epithelial tumors of the liver: An immunohistochemical study. Liver 13:172-176.
8. Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Borresen AL, Cornelisse CJ, Devilee P (1994) Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54:4200-4206.
9. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machinami R (1993) Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375-381.
10. Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T, Machinami R (1994) Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 3:9-14.
11. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
12. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184.
13. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P (1993) Intratumoral microvessel density and p53 protein: Correlation with metastasis in head-and-neek squamous-cell carcinoma. Int J Cancer 55:739-744.
14. Gerken SC, Albertsen H, Elsner T, Ballard L, Holik P, Lawrence E, Moore M, Zhao X, White R (1995) A strategy tor constructing high-resolution genetic maps of the human genome: A genetic map of chromosome 17p, ordered with meiotic breakpoint-mapping panels. Am J Hum Genet 56:484-499.
15. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
16. Hayashi K (1992) PCR-SSCP: A method for detection of mutations. GATA 9:73-79.
17. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, Lips CJM, Buys C (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
18. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) P53 mutations in human cancers. Science 253:49-53.
19. Jennette JC, Wick MR (1989) Immunohistological techniques. In JC Jennette (ed): Immunohistology in Diagnostic Pathology. Boca Raton: CRC Press, pp 1-27.
20. Jones MH, Nakamura Y (1992) Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosom Cancer 5:89-90.
21. Khosla S, Patel VM, Hay ID, Schaid DJ, Grant CS, van HJ, Thibodeau SN (1991) Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 87:1691-1699.
22. Landsvater RM, Mathew CG, Smith BA, Marcus EM, te Meerman GJ, Lips CJ, Geerdink RA, Nakamura Y, Ponder BA, Buys CH (1989) Development of multiple endocrine neoplasia type 2A does not involve substantial deletions of chromosome 10. Genomics 4:246-250.
23. Lin SR, Lee YJ, Tsai JH (1994) Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 78:483-491.
24. Mazars GR, Jeanteur P, Lynch HT, Lenoir G. Theillet C (1992) Nucleotide sequence polymorphism in a hotspot mutation region of the p53 gene. Oncogene 7:781-782.
25. Merlo GR, Venesio T, Bernardi A, Cropp CS, Diella F, Cappa AP, Callahan R, Liscia DS (1994) Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas. Cancer Genet Cytogenet 76:106-111.
26. Moley JF, Brother MB, Fong CT, White PS, Baylin SB, Nelkin B, Wells SA, Brodeur GM (1992) Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 52:770-774.
27. Mulligan LM, Gardner E, Smith BA, Mathew CG, Ponder BA (1993a) Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes Chromosom Cancer 6:166-177.
28. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ (1993b) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
29. Myers RM, Larin Z, Maniatis T (1985) Detection of single base substitution by ribonuclease cleavage at mismatches in RNA: DNA duplexes. Science 230:1242-1246.
30. Nakamura Y, Ballard L, Leppert M, O'Connell P, Lathrop GM, Lalouel JM, White R (1988a) Isolation and mapping of a polymorphic DNA sequence (pYNZ22) on chromosome 17p [D17S30]. Nucleic Acids Res 16:5707.
31. Nakamura Y, Lathrop M, O'Connell P, Leppert M, Barker D, Wright E, Skolnick M, Kondoleon S, Litt M, Lalouel JM, White R (1988b) A mapped set of DNA markers for human chromosome 17. Genomics 2:302-309.
32. Nelkin BD, Nakamura Y, White RW, de Bustros AC, Herman J, Wells SA, Jr., Baylin SB (1989) Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma. Cancer Res 49:4114-4119.
33. Oliphant AR, Wright EC, Swensen J, Gruis NA, Goldgar D, Skolnick MH (1991) Dinucleotide repeat polymorphism at the D17S513 locus. Nucleic Acids Res 19:4744.
34. Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, Steinbrueck T, Wallace M, Wells SA Jr, Donis-Keller HR (1993) Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 53:2947-2949.
35. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383.
36. Shi SR, Key ME, Karla KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating on tissue sections. J Histochem Cytochem 39:741-748.
37. Shi CY, Phang TW, Ngoi SS, Wee A, Li B, Lin Y, Lee HP, Ong CN (1994) Characterization of p53 gene mutations in colorectal carcinomas from an Asian population. Anticancer Res 14:2811-2816.
38. Thor AD, Moore DH, II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS (1492) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer lnst 84:845-855.
39. Tsuda H, Hirohashi S (1992) Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res 83:1184-1191.
40. Winter E, Yamamoto F, Almoguera C, Perucho M (1985) A method to detect and characterize point mutations in transcribed genes: Amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells. Proc Natl Acad Sci USA 82:7575-7579.
41. Yana I, Nakamura T, Shin E, Karakawa K, Kurahashi H, Kurita Y, Kobayashi T, Mori T, Nishisho I, Takai S (1992) Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma. Jpn J Cancer Res 83:1113-1116.
42. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M (1992) Role of p53 mutations in endocrine tumorigencsis: Mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res 52:5061-5064.